ArticleTransfusion2019
Type 1 IFN signaling critically regulates influenza-induced alloimmunization to transfused KEL RBCs in a murine model.
Article in Transfusion, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 19 citations in OpenAlex.
- Anti-Erythrocyte Antibody Formation in Individuals With and Without Known Sensitisation Pathways Reflecting Indications for Extended Immunohaematology Screening.Journal of clinical laboratory analysis · 2026Article
- Suppression of RBC alloimmunization and regulation of CD4Transfusion · 2026Article
- Examining Inflammatory Effects of Reticulocyte Erythrophagocytosis in Human Macrophage Cultures.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The Immunology of Transfusion Medicine: Past, Present, and Future.Methods in molecular biology (Clifton, N.J.) · 2026Review
- The Nrf2 Activator CDDO-Imidazole Suppresses Inflammation-Induced Red Blood Cell Alloimmunization.Antioxidants (Basel, Switzerland) · 2025Article
- CDDO-Imidazole regulates RBC alloimmunization to the KEL antigen by activating Nrf2.bioRxiv : the preprint server for biology · 2025Article
- A spleen is required for antibody mediated immune enhancement but not for RBC clearance or antigen-modulation in mice.Transfusion · 2025Article
- Research progress in RBC alloimmunization.Frontiers in immunology · 2025Review
- Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice.The Journal of clinical investigation · 2024Article
- The Development and Consequences of Red Blood Cell Alloimmunization.Annual review of pathology · 2023Review
- Alloantigen Copy Number as a Critical Factor in RBC Alloimmunization.Transfusion medicine reviews · 2023Review
- Distinct RBC alloantibody responses in type 1 interferon-dependent and -independent lupus mouse models.Frontiers in immunology · 2023Article
- Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease.EJHaem · 2021Article
- Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients.Blood advances · 2021Article
- Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease.Frontiers in medicine · 2021Article
- Antibodies to Low-Copy Number RBC Alloantigen Convert a Tolerogenic Stimulus to an Immunogenic Stimulus in Mice.Frontiers in immunology · 2021Article
- Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction.Annals of blood · 2020Article
- Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice.Blood · 2020Article
- Type 1 Interferon Gene Signature Promotes RBC Alloimmunization in a Lupus Mouse Model.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundOnly a fraction of red blood cell (RBC) transfusion recipients form alloantibodies, and variables determining responsiveness or nonresponsiveness are poorly understood. We and others have previously shown in animal models that pretreatment with toll-like receptor agonists that mimic different types of infections impacts the magnitude or frequency of RBC alloantibody responses. We hypothesized that influenza infection, coexistent with transfusion, would impact responses to transfused RBCs in a manner dependent on Type 1(α/β) interferon (IFN) signaling and tested this in a murine model. STUDY DESIGN AND
methodsWild-type mice or mice lacking the ability to respond to Type 1 IFN were infected with influenza prior to the transfusion of transgenic murine RBCs (K1) expressing the human KEL glycoprotein or the triple fusion HOD protein. Alloantibody responses were measured longitudinally after transfusion by flow cytometric crossmatch, and posttransfusion RBC recovery and survival was evaluated.
resultsInfluenza-infected mice transfused with K1 RBCs developed robust anti-KEL alloantibodies, whereas animals transfused in the absence of infection remained nonresponders; influenza-associated RBC alloimmunization was also observed after transfusion of HOD RBCs. Recipient Type 1 IFN production was critical to the mechanism of action of influenza-induced RBC alloimmunization, with alloimmunization being significantly decreased in mice unable to sense Type 1 IFN (through antibody blockade or genetic approaches).
conclusionThese and other data suggest that Type 1 IFN responses to toll-like receptor agonists or infections regulate RBC alloantibody responses. Studies investigating whether such a correlation exists in humans may be informative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.